There is growing consensus regarding their evolving role in Ph-like B-ALL (PTKi: ABL1, SRC, TRK, FLT3 and JAK inhibitors) and pre-B ALL with t(1;19) (PTKi: BTK and SRC inhibitors)[30-53] [Table 1]. Here, ABL1 is linked to acute lymphoblastic leukemia.